Advertisement

AbbVie report to update hepatitis C drug war

By Bob Herman  |  April 18, 2015

Pharmaceutical company AbbVie will unveil its first-quarter earnings Thursday, giving investors and industry observers their first glimpse of what a full quarter of sales looks like for its new hepatitis C treatment.

FDA approves first generic version of leading MS drug Copaxone

By Steven Ross Johnson  |  April 16, 2015

Novartis subsidiary Sandoz received approval from the Food and Drug Administration Thursday to market the drug Glatopa, the first generic alternative for Teva Pharmaceutical's multiple sclerosis treatment Copaxone.

PhRMA CEO Castellani announces retirement

PhRMA CEO Castellani announces retirement

By Steven Ross Johnson  |  April 16, 2015

John Castellani, Pharmaceutical Research and Manufacturers of America president and CEO, plans to retire from the post at the beginning of next year.

Specialty drugs, Medicaid expansion drive jump in prescription spending

By Steven Ross Johnson  |  April 14, 2015

Spending in the U.S. on prescription drugs rose by 13% in 2014, driven largely by increased spending on new breakthrough medications, according to a new report. And Medicaid patients' spending on drugs rose much faster in states that expanded Medicaid under the ACA compared with those that did not.

Panel recommends labeling change for AstraZeneca's diabetes drug Onglyza

By Steven Ross Johnson  |  April 14, 2015

An advisory panel to the U.S. Food and Drug Administration voted Tuesday to recommend the agency require drugmaker AstraZeneca to change the labeling of its diabetes medication Onglyza to add safety information to reflect a heightened risk for heart failure associated with its use.

CDC launches new Ebola vaccine trial in Sierra Leone

By Steven Ross Johnson  |  April 14, 2015

The Centers for Disease Control and Prevention said Tuesday that it has launched a clinical trial in Sierra Leone of the experimental Ebola vaccine that showed positive results in two previous trials.

AstraZeneca diabetes drug may increase risk of heart failure and death

By Steven Ross Johnson  |  April 10, 2015

A preliminary report by the U.S. Food and Drug Administration said AstraZeneca's diabetes drug Onglyza was associated with a higher risk of death and heart failure, raising new concerns over a class of diabetes medications that has been linked to heart failure complications.

Mylan offers to buy Perrigo for $28.9 billion

By Associated Press  |  April 08, 2015

In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.

FDA ushers in the biosimilar era; now let's get the names right

FDA ushers in the biosimilar era; now let's get the names right

By Dr. Bert Petersen  |  April 06, 2015

Last month, the Food and Drug Administration approved the first biosimilar in the U.S.—Sandoz's Zarxio, a biosimilar version of Amgen's Neupogen (filgrastim). This effectively launches a new industry—one where lower-cost biosimilars will eventually create a competitive market.

Opposition continues against proposed FDA generic label rule

By Virgil Dickson  |  March 31, 2015

Major pharmaceutical companies continue to actively oppose a yet-to-be-finalized proposed rule that would require generic drug companies to update labels on products if they receive new safety information.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.